Brings more than 25 years of experience advancing and commercializing high-impact therapies for seri

FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evalu

FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evalu

4,302 common shares were exercised and sold on June 17, 2026, for $476,000 at a weighted average pri

FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evalu

Palvella remains on track to submit an NDA in the second half of 2026Microcystic lymphatic malformat

Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biop

Stephens & Co. analyst Sudan Loganathan reiterates Palvella Therapeutics (NASDAQ:PVLA) with a

In SELVA Phase 3 study, 100% of participants (13/13) aged 6–11 years were rated as "Much Improve

100% of patients with bleeding at baseline demonstrated a statistically significant improvement on t

The transfer is effective at the opening of trading on Wednesday, May 13, 2026. The Company's co

Stephens & Co. analyst Sudan Loganathan initiates coverage on Palvella Therapeutics (NASDAQ:P

Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.20) per share which missed the

Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformat

James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children's Hospital of

Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy

Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.08) per share which missed the

Palvella Therapeutics, Inc. (Palvella or "the Company") (Nasdaq: PVLA), a clinical-stage bio

HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with

Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella's lea

Mizuho analyst Graig Suvannavejh maintains Palvella Therapeutics (NASDAQ:PVLA) with a Outperform

BTIG analyst Jeet Mukherjee maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises

Palvella Therapeutics, Inc. ("Palvella") (Nasdaq: PVLA), a clinical-stage biopharmaceutical

Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy

HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with

Palvella Therapeutics shares are trading higher after reporting topline data from its Phase 3 SELVA

Primary endpoint met with statistically significant improvement (mean change of +2.13; p<0.001) o

Publication includes a systematic review of 24 studies describing off-label cutaneous application of

BTIG analyst Jeet Mukherjee reiterates Palvella Therapeutics (NASDAQ:PVLA) with a Buy and mainta

BTIG analyst Jeet Mukherjee reiterates Palvella Therapeutics (NASDAQ:PVLA) with a Buy and mainta

Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcys

Mizuho analyst Graig Suvannavejh initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a

Truist Securities analyst Danielle Brill maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy

Canaccord Genuity analyst Whitney Ijem maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy a

TD Cowen analyst Ritu Baral maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises t

(Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage bio

Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy

HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with

Palvella Therapeutics reports Phase 2 data showing 73% improvement with QTORIN rapamycin gel in cuta

Clear Street analyst Kaveri Pohlman initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) wit